Reading time: 2 minutesShareholders once again took part in a consultative vote on Roche’s Remuneration Report. The report was approved with 99% of the votes represented.
DeAnne Julius and Beatrice Weder di Mauro were re-elected to the Board for another three- year term. William M. Burns and Arthur D. Levinson were elected as new members of the Board. Peter Brabeck and Horst Teltschik did not stand for re-election to the Board.
Franz B. Humer, Chairman of the Board of Directors, said: “We are grateful to Peter Brabeck and Horst Teltschik for their exceedingly valuable contributions as Board members over the years. With the successful completion of the Genentech transaction and a consistent focus on our two core businesses – Pharmaceuticals and Diagnostics – Roche is extremely well placed for the future.”
Severin Schwan said: “I’m delighted that we’ve been able to complete the integration of Genentech rapidly and successfully. We further strengthened our market position in 2009 and are off to a good start this year. Roche has one of the strongest product pipelines in the industry, and we will continue to rely on scientific and research excellence in the future.”
Editor's note: Image rights belong to the respective publisher.
Source: Roche, Press release